Heart failure & cardiomyopathiesMeta-analysis
Impact of Comorbidities on Health Status Measured Using the Kansas City Cardiomyopathy Questionnaire in Patients with Heart Failure with Reduced and Preserved Ejection Fraction
- Pooled individual-patient-data analysis of HFrEF and HFpEF randomised trials
- ATMOSPHERE, PARADIGM-HF, DAPA-HF (HFrEF)
- TOPCAT, PARAGON-HF (HFpEF)
Authors' conclusion
Cardiac and non-cardiac comorbidities are common in both HFrEF and HFpEF patients and most are associated with reductions in health status although the impact varied among comorbidities, by the number of comorbidities, and by HF phenotype.
Study context
- Population
- Patients with HFrEF or HFpEF enrolled in the ATMOSPHERE, PARADIGM-HF, DAPA-HF, TOPCAT and PARAGON-HF trials
- Participants
- 20,159 vs 6,563
- Comparison
- Kansas City Cardiomyopathy Questionnaire (KCCQ) scores by comorbidity and heart failure (HF) phenotype
- HFrEFn = 20,159reference
- HFpEFn = 6,563
- Outcome
- KCCQ domain scores and overall summary score (KCCQ-OSS) across comorbidities
Pooled result
As reported in the abstract
KCCQ-OSS
| Group | Value | KCCQ-OSS, 0 comorbidities | KCCQ-OSS, ≥4 comorbidities |
|---|---|---|---|
| HFrEF | 71.3 | 76.8 | 66.4 |
| HFpEF | 67.8 | 73.7 | 65.2 |
Further pooled results
Comorbidity prevalence
AF
CKD
Diabetes
Obesity
Angina
COPD
Stroke
Anaemia
Original publication
Impact of Comorbidities on Health Status Measured Using the Kansas City Cardiomyopathy Questionnaire in Patients with Heart Failure with Reduced and Preserved Ejection Fraction. Eur J Heart Fail. Published 3 August 2023. doi:10.1002/ejhf.2962
Summarised from the published abstract; every number is checked against it